|Last Price||Today's Change||52-Week Range||Trading Volume|
|55.37||0.42 (+0.76%)||45.69 - 63.62||12.8 million (Below Avg)|
Market data as of 4:03PM 08/28/15. Quotes are delayed by at least 15 min.
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
08/20/2015 8:30 AM ET
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
08/18/2015 8:00 AM ET